Zidevin® (Tablets) Instructions for Use
Marketing Authorization Holder
LASA Laboratorios, LLC (Russia)
Manufactured By
Velpharm, LLC (Russia)
ATC Code
N07BB (Drugs used for alcohol dependence)
Active Substance
Metadoxine (Grouping name)
Dosage Form
| Zidevin® | Tablets 500 mg: 10, 20, 30, 40, 50, or 60 pcs. |
Dosage Form, Packaging, and Composition
Tablets oval, biconvex, white in color.
| 1 tab. | |
| Metadoxine | 500 mg |
Excipients: microcrystalline cellulose 112, sodium stearyl fumarate, colloidal silicon dioxide (aerosil).
10 pcs. – blister pack (1) – cardboard packs.
10 pcs. – blister pack (2) – cardboard packs.
10 pcs. – blister pack (3) – cardboard packs.
10 pcs. – blister pack (4) – cardboard packs.
10 pcs. – blister pack (5) – cardboard packs.
10 pcs. – blister pack (6) – cardboard packs.
10 pcs. – jar (1) – cardboard packs.
20 pcs. – jar (1) – cardboard packs.
30 pcs. – jar (1) – cardboard packs.
40 pcs. – jar (1) – cardboard packs.
50 pcs. – jar (1) – cardboard packs.
60 pcs. – jar (1) – cardboard packs.
Clinical-Pharmacological Group
Hepatoprotective agent. Drug used for alcohol dependence
Pharmacotherapeutic Group
Other agents for the treatment of nervous system diseases; agents used for addictive disorders; agents used for alcohol dependence
Pharmacological Action
Anti-alcohol, hepatoprotective and detoxifying agent, a derivative of pyridoxine (vitamin B6). It accelerates the elimination of ethanol and acetaldehyde from the body and activates enzymes involved in ethanol metabolism.
It restores the ratio of saturated and unsaturated free fatty acids in plasma and prevents primary structural degeneration of hepatocytes; it inhibits the formation of fibronectin and collagen, preventing the development of liver fibrosis and cirrhosis.
It reduces the pathological craving for ethanol, reduces the severity of mental and somatic symptoms of hangover, and shortens the time for relief of alcohol withdrawal syndrome.
It normalizes the detoxification function of the liver, improves the mental state of patients, and causes regression of depressive symptoms. It creates conditions for obtaining favorable results when conducting psychocorrective settings to change the alcoholic stereotype.
Pharmacokinetics
Absorption is high, bioavailability is 60-80%, plasma protein binding is 50%, T1/2 is 40-60 min. It is metabolized in the liver to active metabolites – pyridoxine and pyrrolidone carboxylate.
It is excreted by the kidneys – 45-50% within 24 hours; through the gastrointestinal tract – 35-50% within 96 hours.
Indications
Acute alcohol intoxication, alcohol withdrawal syndrome, asthenodepressive conditions of non-psychotic nature.
As part of combination therapy – liver diseases of various etiologies.
ICD codes
| ICD-10 code | Indication |
| F10.0 | Mental and behavioral disorders due to alcohol use – acute intoxication |
| F10.3 | Withdrawal state |
| F48.0 | Neurasthenia |
| K70 | Alcoholic liver disease |
| K73 | Chronic hepatitis, not elsewhere classified |
| ICD-11 code | Indication |
| 6A8Z | Affective disorders, unspecified |
| 6C40.3 | Alcohol intoxication (inebriation) |
| 6C40.4Z | Alcohol withdrawal syndrome, unspecified |
| DB94.Z | Alcoholic liver disease, unspecified |
| DB97.2 | Chronic hepatitis, not elsewhere classified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
For acute alcohol intoxication – 600 mg IM or 600-900 mg IV drip, over 1.5 hours (diluted in 500 ml of 0.9% sodium chloride solution or 5% dextrose solution), once a day.
For alcohol withdrawal syndrome – 900 mg IV drip, once a day, for 3-7 days, depending on the severity of the patient’s condition.
For alcoholic hepatopathy, when conducting maintenance anti-relapse therapy for chronic alcoholism – IM, 500 mg, 3 times a day. The minimum duration of treatment is 90 days.
Liver diseases and asthenodepressive conditions – orally, 500 mg 3 times a day, duration of administration – at least 90 days.
Adverse Reactions
Possible allergic reactions.
Contraindications
Pregnancy, lactation period, hypersensitivity to metadoxine.
Use in Pregnancy and Lactation
Contraindicated for use during pregnancy and during the lactation (breastfeeding) period.
Special Precautions
Use with caution in patients receiving antiparkinsonian drugs.
Drug Interactions
With simultaneous use, it reduces the effectiveness of levodopa.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Kagocel pills 12mg, 30pcs
Phenibut-Vertex pills 250mg, 20pcs
Belosalic, lotion solution for external use spray 100ml
Noopept, pills 10mg, 50pcs
OKI, sachets 80mg 2g, 12pcs
Mildronate capsules 500mg, 90pcs
Fenotropil pills 100mg, 60pcs
Belosalic, ointment, 30g
Daivobet, ointment, 30g
Cavinton Comfort, dispersible pills 10mg 90pcs
Cortexin, 10mg, 5ml, 10pcs
Actovegin pills 200mg, 50pcs
Nootropil pills 800mg, 30pcs
No-spa pills 40mg, 64pcs 